Corline Biomedical AB

OM:CLBIO Stock Report

Market Cap: SEK 486.1m

Corline Biomedical Valuation

Is CLBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CLBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SEK 55.87
Fair Value
64.5% undervalued intrinsic discount
1
Number of Analysts

Below Fair Value: Insufficient data to calculate CLBIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CLBIO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLBIO?

Key metric: As CLBIO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CLBIO. This is calculated by dividing CLBIO's market cap by their current revenue.
What is CLBIO's PS Ratio?
PS Ratio48.5x
SalesSEK 10.02m
Market CapSEK 486.14m

Price to Sales Ratio vs Peers

How does CLBIO's PS Ratio compare to its peers?

The above table shows the PS ratio for CLBIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.3x
ENZY Enzymatica
10.8xn/aSEK 541.3m
IRLAB A IRLAB Therapeutics
3.2x13.36%SEK 242.1m
CINPHA Cinclus Pharma Holding
20.9x40.90%SEK 807.0m
ORX Orexo
2.4x2.67%SEK 1.3b
CLBIO Corline Biomedical
48.5x61.49%SEK 486.1m

Price-To-Sales vs Peers: CLBIO is expensive based on its Price-To-Sales Ratio (48.5x) compared to the peer average (9.3x).

Price to Sales Ratio vs Industry

How does CLBIO's PS Ratio compare vs other companies in the SE Pharmaceuticals Industry?

11 CompaniesPrice / SalesEstimated GrowthMarket Cap
SECARE Swedencare
2.1x9.91%US$587.11m
ORX Orexo
2.4x2.67%US$141.85m
INDEX InDex Pharmaceuticals Holding
2.7xn/aUS$27.34m
PMED PEPTONIC medical
2.3xn/aUS$8.45m
CLBIO 48.5xIndustry Avg. 4.2xNo. of Companies11PS01224364860+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CLBIO is expensive based on its Price-To-Sales Ratio (48.5x) compared to the European Pharmaceuticals industry average (4.2x).

Price to Sales Ratio vs Fair Ratio

What is CLBIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLBIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio48.5x
Fair PS Ratio12.6x

Price-To-Sales vs Fair Ratio: CLBIO is expensive based on its Price-To-Sales Ratio (48.5x) compared to the estimated Fair Price-To-Sales Ratio (12.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

SEK 33
Fair Value
39.8% undervalued intrinsic discount
1
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/05 20:00
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Corline Biomedical AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gustaf MeyerRedeye